GNCP logo

GNCC Capital, Inc. (GNCP)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

GNCC Capital, Inc. (GNCP) with AI Score 48/100 (Weak). GNCC Capital, Inc. , through its subsidiary, focuses on producing and selling cannabis CBD pharmaceutical grade oils. Market cap: 0, Sector: Basic materials.

Last analyzed: Mar 18, 2026
GNCC Capital, Inc., through its subsidiary, focuses on producing and selling cannabis CBD pharmaceutical grade oils. The company distributes its products through channels in Colombia and throughout Latin America.
48/100 AI Score

GNCC Capital, Inc. (GNCP) Materials & Commodity Exposure

HeadquartersLas Vegas, United States
IndustryGold

GNCC Capital, Inc. operates in the basic materials sector, specifically focusing on the production and distribution of cannabis CBD pharmaceutical grade oils in Colombia and Latin America. The company faces significant competition and regulatory hurdles in the evolving cannabis market.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 18, 2026

Investment Thesis

GNCC Capital, Inc. presents a speculative investment opportunity within the cannabis CBD pharmaceutical sector in Latin America. The company's focus on pharmaceutical-grade CBD oils positions it to potentially capture a segment of the market demanding high-quality products. However, the company's small market capitalization of $0.01 billion and negative beta of -38.68 indicate high volatility and sensitivity to market movements. Growth depends on successful navigation of regulatory hurdles, securing distribution partnerships, and scaling production efficiently. Investors should carefully consider the risks associated with investing in a micro-cap company operating in a rapidly evolving and highly regulated industry.

Based on FMP financials and quantitative analysis

Key Highlights

  • GNCC Capital, Inc. operates in the cannabis CBD pharmaceutical sector through its subsidiary BioCann Pharma S.A.S.
  • The company focuses on producing and selling cannabis CBD pharmaceutical grade oils.
  • GNCC Capital distributes its products through channels in Colombia and throughout Latin America.
  • The company is based in Las Vegas, Nevada.
  • GNCC Capital has a market capitalization of $0.01 billion.

Strengths

  • Focus on pharmaceutical-grade CBD oils.
  • Distribution network in Colombia and Latin America.
  • Potential for growth in the expanding cannabis market.
  • Expertise in cannabis cultivation and processing.

Weaknesses

  • Small market capitalization.
  • Dependence on a single subsidiary.
  • Limited product diversification.
  • Negative beta indicating high volatility.

Catalysts

  • Upcoming: Potential regulatory changes in Latin American countries regarding cannabis legalization.
  • Ongoing: Increasing acceptance of CBD products for medical use.
  • Ongoing: Expansion of distribution network in Latin America.

Risks

  • Potential: Regulatory setbacks in the cannabis industry.
  • Potential: Intense competition from established pharmaceutical companies.
  • Potential: Fluctuations in the price of cannabis and CBD.
  • Ongoing: Dependence on a single subsidiary for revenue generation.
  • Ongoing: Negative beta indicating high volatility.

Growth Opportunities

  • Expansion into New Latin American Markets: GNCC Capital can expand its distribution network to other Latin American countries, capitalizing on the increasing acceptance of CBD products in the region. The Latin American cannabis market is projected to experience significant growth, offering opportunities for GNCC Capital to increase its market share and revenue. Timeline: Within the next 3-5 years.
  • Development of New CBD Products: GNCC Capital can invest in research and development to create new CBD-based pharmaceutical products, catering to specific medical conditions and patient needs. This diversification can enhance the company's product portfolio and attract a wider customer base. The global CBD market is expected to continue expanding, driven by increasing awareness of its potential health benefits. Timeline: Ongoing.
  • Strategic Partnerships with Pharmaceutical Companies: GNCC Capital can form strategic alliances with established pharmaceutical companies to co-develop and distribute its CBD products. These partnerships can provide access to established distribution channels, regulatory expertise, and marketing resources, accelerating market penetration. The pharmaceutical industry is increasingly exploring the potential of cannabis-based therapies. Timeline: Within the next 2-3 years.
  • Vertical Integration of Supply Chain: GNCC Capital can integrate its supply chain by acquiring or establishing its own cultivation and processing facilities. This vertical integration can improve quality control, reduce costs, and ensure a consistent supply of raw materials. The cannabis industry is increasingly emphasizing the importance of supply chain management. Timeline: Ongoing.
  • Focus on Pharmaceutical-Grade Quality: By maintaining a strict focus on producing pharmaceutical-grade CBD oils, GNCC Capital can differentiate itself from competitors and attract customers seeking high-quality products. The pharmaceutical sector demands rigorous quality standards, providing a barrier to entry for less sophisticated producers. Timeline: Ongoing.

Opportunities

  • Expansion into new Latin American markets.
  • Development of new CBD-based pharmaceutical products.
  • Strategic partnerships with pharmaceutical companies.
  • Vertical integration of supply chain.

Threats

  • Regulatory uncertainty in the cannabis industry.
  • Intense competition from established pharmaceutical companies and other cannabis producers.
  • Fluctuations in the price of cannabis and CBD.
  • Potential for negative publicity or product recalls.

Competitive Advantages

  • Focus on pharmaceutical-grade CBD oil production.
  • Established distribution channels in Colombia and Latin America.
  • Expertise in navigating the regulatory landscape of the cannabis industry.
  • Potential for brand recognition and customer loyalty through consistent product quality.

About GNCP

GNCC Capital, Inc., based in Las Vegas, Nevada, operates through its subsidiary, BioCann Pharma S.A.S., to produce and distribute cannabis CBD pharmaceutical grade oils. The company focuses on serving the Latin American market, primarily Colombia, through established distribution channels. GNCC Capital aims to capitalize on the growing demand for CBD products in the pharmaceutical sector within the region. The company's business model centers around cultivating, processing, and distributing high-quality CBD oils that meet pharmaceutical standards. GNCC Capital navigates the complex regulatory landscape of the cannabis industry in Latin America to ensure compliance and market access. The company's success hinges on its ability to maintain consistent product quality, secure distribution partnerships, and adapt to evolving regulations in the cannabis market.

What They Do

  • Produces cannabis CBD pharmaceutical grade oils.
  • Sells products through distribution channels.
  • Operates primarily in Colombia and throughout Latin America.
  • Focuses on the pharmaceutical sector.
  • Cultivates and processes CBD oils.
  • Navigates the regulatory landscape of the cannabis industry.

Business Model

  • Cultivation and processing of cannabis plants to extract CBD oil.
  • Manufacturing of pharmaceutical-grade CBD oil products.
  • Distribution of products through established channels in Colombia and Latin America.
  • Revenue generation through the sale of CBD oil products to distributors and end-users.

Industry Context

GNCC Capital, Inc. operates within the evolving cannabis industry, specifically targeting the CBD pharmaceutical sector in Latin America. The global cannabis market is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis for medical and recreational purposes. However, the industry faces challenges such as regulatory uncertainty, intense competition, and varying consumer preferences. GNCC Capital's success depends on its ability to navigate these challenges and establish a strong presence in its target markets. The competitive landscape includes both established pharmaceutical companies and emerging cannabis producers.

Key Customers

  • Pharmaceutical companies seeking high-quality CBD ingredients.
  • Distributors of pharmaceutical products in Colombia and Latin America.
  • Patients seeking CBD-based treatments for various medical conditions.
  • Retailers of health and wellness products.
AI Confidence: 64% Updated: Mar 18, 2026

Financials

Chart & Info

GNCC Capital, Inc. (GNCP) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNCP.

Price Targets

Wall Street price target analysis for GNCP.

MoonshotScore

48/100

What does this score mean?

The MoonshotScore rates GNCP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

GNCP OTC Market Information

GNCP trades on the OTC Other market tier of OTC Markets.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown

Common Questions About GNCP

What does GNCC Capital, Inc. do?

GNCC Capital, Inc., through its subsidiary BioCann Pharma S.A.S., focuses on the production and distribution of pharmaceutical-grade CBD oils. The company operates primarily in Colombia and throughout Latin America, targeting the growing demand for CBD products in the pharmaceutical sector. GNCC Capital aims to establish itself as a reliable supplier of high-quality CBD oils, navigating the complex regulatory landscape of the cannabis industry in the region. The company's success depends on its ability to maintain consistent product quality, secure distribution partnerships, and adapt to evolving regulations.

What do analysts say about GNCP stock?

AI analysis is currently pending for GNCP. Given the company's micro-cap status and focus on the evolving cannabis market, analysts would likely focus on factors such as regulatory approvals, market penetration in Latin America, and the company's ability to scale production efficiently. Key valuation metrics would include revenue growth, gross margins, and profitability. Investors should conduct thorough due diligence and consider the risks associated with investing in a small company operating in a rapidly changing industry.

What are the main risks for GNCP?

GNCC Capital, Inc. faces several risks inherent in the cannabis industry, including regulatory uncertainty, intense competition, and fluctuations in the price of cannabis and CBD. The company's small market capitalization and dependence on a single subsidiary also pose significant risks. Furthermore, GNCC Capital's negative beta indicates high volatility, making it susceptible to market downturns. Investors should carefully consider these risks before investing in GNCP.

What are the key factors to evaluate for GNCP?

GNCC Capital, Inc. (GNCP) currently holds an AI score of 48/100, indicating low score. Key strength: Focus on pharmaceutical-grade CBD oils.. Primary risk to monitor: Potential: Regulatory setbacks in the cannabis industry.. This is not financial advice.

How frequently does GNCP data refresh on this page?

GNCP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven GNCP's recent stock price performance?

Recent price movement in GNCC Capital, Inc. (GNCP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on pharmaceutical-grade CBD oils.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider GNCP overvalued or undervalued right now?

Determining whether GNCC Capital, Inc. (GNCP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying GNCP?

Before investing in GNCC Capital, Inc. (GNCP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Information is based on limited available data.
  • AI analysis is pending.
Data Sources

Popular Stocks